Pathomolecular Analysis of Rare EGFR Mutations in Advanced NSCLC

Completed

• Conditions: Mutations in Exons 18 to 21

• Registration Number: NCT01215474
• Lead Sponsor: Provitro GmbH

Brief Summary

While current mutational analyses comprise exons 19 and 21 in which the majority of EGFR-mutations occur, this study aims at investigating the relevance of exon 18 and 20 mutations. Therefore, the investigators analyse 500 routine tumor samples with respect to the above mentioned exons and correlate the results to the clinical outcome. This approach will enable us to potentially identify patients that might in the future benefit from targeted therapy (EGFR-inhibition).

Detailed Description

Not available

Study Timeline

• Status Verified: 2010-10
• Study First Submitted: 2010-10-05
• Study First Submitted QC: 2010-10-05
• Study First Posted: 2010-10-06
• Last Update Submitted: 2011-06-15
• Last Update Posted: 2011-06-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• NSCLC Stadium III-IV

Exclusion Criteria

• no NSCLC or different stadium

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Institute of Pathology, Charité University Medicine Berlin; 🇩🇪 Berlin, Germany